CD8A and acute myeloid leukemia: We found that the interaction between HLA-F, HLA-E, HLA-C, and B/CD8 + T/HSC-Prog/plasma in NK cells is enhanced in AML, suggesting that these immune checkpoints may be potential targets for the future treatment of AML.